Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Therasse

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Journal of the National Cancer Institute|September 7, 2006
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse, Sherene Loi, Laura van't Veer, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Improving cancer outcomes through international collaboration in academic cancer treatment trialsEdward L Trimble, Jeffrey S Abrams, Ralph M Meyer, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamideClaudio Praga, Jonas Bergh, Judith Bliss, et al.
Journal of the National Cancer Institute|September 7, 2006
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse, Sherene Loi, Laura van't Veer, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
RECIST 1.1-Update and clarification: From the RECIST committeeLawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Improving cancer outcomes through international collaboration in academic cancer treatment trialsEdward L Trimble, Jeffrey S Abrams, Ralph M Meyer, et al.
Pageof 4